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INTRODUCTION 
Coronavirus disease-2019 (COVID-19), caused by SARS-
CoV-2, has been declared a global pandemic,(1) and numbers of 
new cases increase daily in Africa (Table 1 for abbreviations).(2) 
From limited data, SARS-CoV-2 involves the cardiovascular 
system in multiple ways.(3) As cardiologists we play a critical 
role in the management of these patients. Cardiovascular 
imaging such as echocardiography, cardiac computed tomo-
graphy (CCT) and cardiovascular magnetic resonance (CMR) 
are central in the diagnosis and management of patients with 
cardiovascular disease (CVD) who may have COVID-19. As 
imagers we physically engage in the investigation and manage-
ment of such patients, especially with echocardiography where 
close contact is inevitable, and this predisposes to increased 
risk of infection. In this review, we highlight the risks associated 
with various non-invasive cardiovascular imaging modalities, 
revise indications for cardiovascular imaging in the COVID-19 
context, and how risks associated with each modality may be 
mitigated based on current guidelines and recommendations 
from experts.
TRANSTHORACIC ECHOCARDIOGRAPHY: 
INDICATIONS, RISKS, RISK MITIGATION, 
PREPARATION OF ECHOCARDIOGRAPHY 
LABORATORY AND PERSONNEL
During the COVID-19 pandemic, indications for all special 
investigations and procedures have to be reconsidered due to 
the increased demand on healthcare resources and the risk of 
infection of healthcare workers (HCW). In terms of transtho-
COVID-19 and cardiovascular 






In the ongoing COVID-19 pandemic, patients with car-
diac disease have been the worst affl icted with a high 
mortality. Cardiac imaging forms an integral part of the 
armamentarium in the management of these patients. 
This review focuses on providing a general guide to car-
diac imaging in the COVID-19 context for the practising 
clinician in Africa. These recommendations are likely 
to be modifi ed as further data emerge on the effect of 
the SARS-CoV-2 virus on the cardiovascular system.
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TABLE I: Abbreviations.
AGP Aerosol generating procedure
CCT Cardiac computed tomography





LAA Left atrial appendage
PPE Personal protective equipment
PUI Persons under investigation
SARS-CoV-2




















racic echocardiography (TTE), this will imply that TTE should 
only be performed if it would influence or alter therapy in the 
short term. TTE should be limited to mostly inpatients, although 
a limited number of outpatients will have a clinical indication 
for TTE.  No routine or follow-up TTE should be performed – 
except if there is a clear clinical indication.
In the outpatient services all patients entering the service from 
home should be screened for symptoms (preferably telephon-
ically and ahead of time if your service can accommodate this, 
or else at the entrance to your service by a dedicated staff 
member).(4) Anyone reporting concerning symptoms should 
have the echo postponed and the local institutional protocol 
for suspected COVID persons activated. Social distancing, of a 
minimum of 1.5m, should be adhered to in your waiting room. 
It is best to set your area up with designated marked areas 
where patients can sit. All patients should wear face masks. No 
companions/family are allowed in the waiting rooms or the 
echo room. 
The risk to HCW performing TTE is significant, although not as 
high as transoesophageal echocardiography (TEE), which is 
considered an aerosol-generating procedure (AGP).(5) The risk 
to HCW performing TTE is a consequence of direct contact 
with the patient, the proximity to the upper respiratory tract 
of the patient, prolonged (>15 minutes) contact with the 
patient, and the contamination of equipment that poses a risk 
during future image acquisitions.
The TTE service in each hospital or practice should be set 
up to minimise the risk of infection to HCW by undiagnosed 
or asymptomatic patients. It is currently not feasible to test 
every patient for COVID-19 before performing an echo-
cardiogram – even if it were possible the false negative rate will 
make this strategy ineffective. Infection with COVID-19 of 
HCW poses a risk to patients in terms of the availability of 
echocardiographic service and the potential risk of nosocomial 
transmission of the virus. Echocardiography skills are limited in 
South Africa and should a significant portion of echocardio-
graphically competent HCW become infected with COVID-19, 
continuity of care will be interrupted. HCW at significant risk of 
developing severe COVID-19 infection should be considered 
for reporting or interpretation of images only and should limit 
and, where possible, avoid patient contact.
For inpatient services, all requests are to be reviewed and 
triaged by a senior clinician in the echo service (fellow or con-
sultant) and prioritised according to medical need in establish-
ing a definitive diagnosis and therapeutic intervention.(6) These 
decisions are to be taken on a case-by-case basis rather than a 
prescribed list of conditions given the fluid nature of the pan-
demic at present. There is a need to review practices on a 
fortnightly basis to adapt protocols and workflow according to 
the needs of the pandemic. Traffic and exposure in the echo-
cardiography laboratory should be minimised as much as 
possible – telephonic and/or electronic requests are preferable. 
Establishing a system for timeously and efficiently transporting 
patients will minimise waiting time of inpatients and risk of 
exposure to staff. The following steps should be followed 
routinely when scanning the undifferentiated patient to mitigate 
the risk of patient to HCW transmission of COVID-19 during 
echocardiography:
 ■ Review the indication for the study.
 ■ All patients should wear a surgical or cloth mask. 
 ■ HCW should wear appropriate personal protective equip-
ment (PPE).(5) 
 ■ If available, use hand-held echocardiography machines.
 ■ The echocardiographer should continue to image from the 
side of the patient that enables them to get relevant images 
in the shortest period of time. Although scanning from the 
right side of the patient is advantageous, a switch from left 
to right side at this stage may prolong scan time.
 ■ Acquire only the minimum data set, and minimise acquisi-
tion time.
 ■ All measurements, post processing and reporting to be per-
formed after patient leaves the room or offline if available.
 ■ Echocardiography machines need to be regularly disinfected 
as per manufacturer’s guidelines.(7,8)
 ■ Regular cleaning of the echocardiography suite.
For patients under investigation for COVID-19 (PUI) or con-
firmed COVID-19 infection, echocardiography should only be 
performed if the result will alter short-term management. 
Examples of indications include: Heart failure/myocarditis, signi-
ficant or life threatening arrhythmias, cardiac tamponade and 
cardiogenic shock or haemodynamic instability. If not, echo-
cardiography should be deferred until after recovery (usually 14 
days). During echocardiography of PUI or confirmed COVID-19 
patients, additional precautions are advised:
 ■ HCW at high risk of developing severe COVID-19 infection 
should not perform echocardiography.
 ■ The most skilled operator available should acquire images.
 ■ Do not transport patients to the echocardiography suite; 
images to be acquired in isolation room (mobile).
 ■ Use dedicated device for COVID-19 patients if possible.
 ■ Use a handheld device, if possible, as disinfection is easier.
 ■ Abbreviated image acquisition protocol to answer the clin-
ical question – no minimum data set.
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 ■ Aim to answer the clinical question using the subcostal 
acoustic window only in ventilated patients.
 ■ Do not attach ECG leads – use time gating.
 ■ If possible, also use individual/disposable gel dispensing 
methods such as gel sachets or syringes. During the scan, if 
availability allows, use disposable plastic probe protectors 
and covers for the machine.(4)
 ■ All post processing, measurements and reporting to be 
performed offline or after doffing.
 ■ Donning and doffing as per protocol.
 ■ Device to be cleaned as per manufacturer’s guidelines.
 ■ Ensure that the machine is stored in a dedicated area away 
from the other machines and equipment utilised for non-
COVID patients.
During the early phase of the pandemic, it makes sense to 
have dedicated echocardiographic machines in COVID-19 
areas to perform TTE. This lowers the risk of spread of the 
virus associated with the movement of equipment. As com-
munity spread of the virus increases, all patients should be 
considered COVID-19 positive – even if they had a recent 
negative nasopharyngeal and oropharyngeal swab, as the nega-
tive predictive value of these swabs is low.
Existing personnel should be risk stratified. Those at higher risk 
(age >60 years, immunocompromised state, cardiorespiratory 
disease, BMI >40) should ideally not be working in the front-
line.(4) All staff should be familiar with the protocols for scanning 
COVID-19 patients, the indications for various levels of per-
sonal protective equipment (PPE), know where to access the 
PPE, as well as how to doff and don the PPE. 
There is a decrease in patients without COVID-19 accessing 
cardiac care, both as a result of the limited availability of the 
services and of patients with cardiac complaints seeking med-
ical care. Several guideline documents highlight the need to 
balance essential cardiovascular services while preserving HCW 
resources during the peak of the COVID-19 pandemic. As the 
pandemic abates, there will be an opportunity to reintroduce 
routine cardiovascular care (of which TTE is an important com-
ponent), with the appropriate safety measures in place.  
We recommend a pragmatic approach to the reintroduction of 
outpatient echocardiography, and that outpatient appoint-
ments are preceded by a short telephonic consultation to 
ensure screening for COVID-19 symptoms and to aid with 
planning of the appointment. During these visits, the standard 
practice of mask wearing, hand sanitation and physical distancing 
should be adhered to.
TRANSOESOPHAGEAL ECHOCARDIOGRAPHY: 
INDICATIONS, RISKS, RISK MITIGATION, 
PREPARATION OF LABORATORY AND 
PERSONNEL
TEE poses a great risk to operators and their team.(9) This is 
due to the inherent greater risk of aerosolisation of virus 
particles – especially during intubation. Urgent indications 
include patients with left-sided infective endocarditis, poor 
imaging quality on trans-thoracic echocardiography, suspected 
prosthetic valve thrombosis or endocarditis where TTE pro-
vides insufficient information. If there is an indication for TEE, 
all patients must be tested for COVID-19 prior to the exam. 
TEE should be avoided in a confirmed case of COVID-19. 
Recently, stroke has emerged as one of the complications 
related to COVID-19 infection. In this context, it is usually 
related to pro-thrombotic milieu and micro-angiopathy asso-
ciated with COVID-19, and is unlikely related to an intra-cardiac 
shunt.(10) Therefore, TEE should be deferred as it is unlikely to 
change diagnosis and management. A TTE bedside bubble 
study may be considered. If any doubt exists, the individual case 
must be discussed with the  heart team.  
In general, the diagnostic investigation should be deferred to an 
imaging modality that is associated with lesser risk, but with the 
similar ability to answer a clinical question as TEE.(11) A classic 
example would be that of a patient requiring cardioversion for 
dysrhythmia, such as atrial fibrillation. For exclusion of throm-
bus in the left atrium (LA) or left atrial appendage (LAA), car-
diac computed tomography (CCT) may be utilised. Further 
elective procedures such as structural heart disease interven-
tion that require guidance with TEE should be postponed 
unless there is urgency or emergency. In the African context, 
this constitutes mostly patients for balloon mitral valvuloplasty 
that present with acute heart failure while pregnant. 
The echocardiography laboratory set-up, and PPE for TEE 
remains the same as for TTE described above. All TEE must 
be ideally performed in a dedicated echocardiography room 
with adequate ventilation and air exchanges. The room and 
the echocardiographic equipment must be cleaned and 
decontaminated post-procedure, according to a standardised 
protocol. 
TEE must be performed by an experienced operator to limit 
the duration of the procedure. Only personnel required to do 
the TEE should be permitted in the room. All HCWs con-
sidered high-risk for getting infected must not be allowed in 
the area when scanning suspected or confirmed cases of 
COVID-19. All teaching of trainees must be postponed, and 
simulation and online videos can be used as substitutes. The 
procedure must be focused and should be terminated once 
the clinical question is answered. Unnecessary equipment at 

















probes, and carotid Doppler probes, must be removed from 
the machine. The machine can be covered with a cloth during 
the procedure to reduce contamination without compromising 
the operator’s view.
CARDIAC COMPUTED TOMOGRAPHY: 
INDICATIONS, RISK ASSESSMENT AND 
MITIGATION 
Patients must be ideally tested for COVID-19 prior to CCT 
examination. CCT may be indicated to diagnose coronary 
artery disease, aortic dissection, pulmonary embolism and left 
ventricular (LV), LA and LAA thrombus due to a hypercoagu-
lable state(10) associated with SARS-CoV-2. Coronary CT angio-
graphy may eliminate the need for invasive coronary catheter-
isation and reduces the risk to catheterisation laboratory 
personnel. Lately, Kawasaki’s disease has emerged as a rare 
complication of COVID-19 infection in children, as part of the 
pro-inflammatory process(12) and CCT may serve as a useful 
non-invasive imaging modality in this sub-group of patients to 
identify aneurysmal involvement of coronary arteries. Any inci-
dental pulmonary finding seen on CCT suggestive of COVID-19 
pneumonia in a patient who was not suspected of having the 
disease must be immediately reported and communicated to 
the referring physician.(13) Due to the CT’s ability to diagnose 
early onset pneumonia in an asymptomatic patient, a routine 
scan of the chest where a patient has an indication for CT is 
recommended.(14)
All elective cases must be postponed, as recommended by 
the Society for Cardiovascular CT (SCCT).(13) Urgent CCT 
indications are described in Table II. Details of indications are 
discussed in the SCCT guidelines.(13) In Africa, most cases of 
chest pain undergo invasive coronary angiography and the role 
of cardiac CT is limited. 
CT scanner room equipment setup and patient transportation 
are described in the SCCT guidelines.(13) Transport of a patient 
to and from the COVID-19 ward must be done as per stan-
dardised protocol of each institution. Patients must not wait 
outside in a general CT laboratory, to reduce infection to other 
personnel and patients.
Staff education, personal protective equipment and decon-
tamination must be done as per SCCT guidance.(13) In health-
care facilities with more multiple CT scanners, one scanner can 
be dedicated to COVID-19 cases. This is not possible in the 
majority of hospitals in Africa and thus strict decontamination 
measures and personal protective measures must be followed.
CARDIOVASCULAR MAGNETIC RESONANCE: 
INDICATIONS, RISK ASSESSMENT AND 
MITIGATION IN THE CONTEXT OF COVID-19 
CMR is a remarkably powerful imaging modality, free of ionising 
radiation, with high spatial and temporal resolution, performed 
via excitation of hydrogen protons within a powerful magnetic 
field. The strong magnetic field aligns the nuclear magnetisa-
tion spin of the hydrogen protons, which are then excited by 
radiofrequency pulses. Fourier transformation is then used to 
convert frequencies into images. Signal from a given tissue 
(e.g. heart muscle) is determined by the proton density and 
2 specif ic relaxation parameters: longitudinal relaxation and 
transverse relaxation times, which vary substantially for different 
tissues, and substantially within the same tissue from health to 
disease.(15)
A CMR scanner consists of a superconducting magnet, a radio-
frequency transmitter and receiver connected to radio aerials, 
and gradient coils driven by powerful pulses of electricity to 
create transient magnetic fields. Scanning sequences are coor-
dinated to the electrocardiographic complexes. Indications and 
contra-indications for CMR are included in Table III. CMR is 
extremely safe, and unequivocally advantageous compared with 
x-ray and scintigraphic techniques. Patients for CMR must be 
screened as ferromagnetic particles may act as potentially 
dangerous projectiles in the vicinity of the scanner. Although 
most metallic medical implants – including all prosthetic cardiac 
valves, stents, conduits, pacemakers and implantable-cardio-
verter defibrillators are MR compatible or conditional – care 
needs to be taken with certain implants like insulin drivers and 
cerebrovascular clips. Gadolinium-based contrast agents have 
proved extremely safe in tens of millions of patients. The risk of 
nephrogenic sclerosing fibrosis appears extremely low, parti-
cularly with the use of cyclic chelates.(16)
Healthcare workers in the MR suite are at increased risk of 
infection from contact with patients infected with SARS-CoV-2, 
as placement of leads puts them in very close physical contact 
with patients. COVID-19 is transmitted from person to person 
through small droplets from the nose or mouth, spread when 
a person with COVID-19 coughs or exhales. Droplets land 
on objects and surfaces around the person, and the virus may 
remain viable on hard surfaces for days (others may catch 
COVID-19 by touching these objects or surfaces).(17) Impor-
tantly, asymptomatic individuals are still capable of transmitting 
TABLE II: Urgent Indications for cardiac computed tomography 
in the COVID-19 context.
Coronary artery disease assessment in high-risk patient




Prosthetic valve thrombosis and endocarditis
Patient requiring urgent structural heart disease intervention 
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the virus. The Society for Cardiovascular Magnetic Resonance 
(https://scmr.org/page/COVID19), European Association of 
Cardiovascular Imaging (https://www.escardio.org/The-ESC/
Press-Office/Press-releases/ESC-Guidance-for-the-Diagnosis-
and- Management-of-Hear t -Disease -during -COVID-19), 
and American College of Radiology [ACR] (https://www.acr.org/
Clinical-Resources/Radiology -Safety/MR-Safety/COVID-19 
and-MR-Use) recommend that CMR should be avoided in 
patients with COVID-19, or in persons under investigation, to 
minimise risk to healthcare workers, unless the test is absolutely 
necessary and is the only diagnostic tool that can be used, and 
imaging is likely to impact imminent clinical management.(11) All 
other studies should be delayed or alternative imaging methods 
such as point-of-care or portable ultrasound or CT considered. 
If patients do have a CMR study, appropriate PPE should be 
worn by imaging staff and patients should also wear a standard 
surgical or cloth mask, and shortened protocols should be 
used.(18) Whenever possible, the imaging department should 
dedicate a specific area (including waiting space) and specific 
equipment (e.g. MR scanner) to the evaluation of patients 
with suspected or confirmed COVID-19, to minimise the risk of 
contamination of other patients and to concentrate the 
protective material availability.
The ACR has also recommended for the following:
 ■ Cleaning of MR machines: while instructions and strategies 
for cleaning and disinfecting MR machines (with water 
and soap or alcohol-based disinfectants) will vary by loca-
tion and the availability of  PPE, the ACR recommends 60 
minutes of down-time between patients and after all sur-
faces have been thoroughly cleaned.
 ■ PPE: powered air-purifying ventilators should not be 
brought into the vicinity of the scanner, as these contain 
ferromagnetic components.
 ■ Masks: inpatients who have metal strips on masks should 
be fitted with MRI-safe alternatives, and metallic strips 
should be removed from face masks and replaced with 
tape. 
In some hospitals, the use of a mobile CT unit close to the 
location where clinical triage is performed at the entrance to 
the hospital might be considered, depending on the availability 
of access to standard CT equipment.
The approach to cardiac imaging in COVID-19 is summarised 
in Figure 1.
CONCLUSIONS 
Cardiac imaging is an essential service in patient care, not only 
in patients presenting with cardiac conditions, but across the 
spectrum of medicine. This holds true in the COVID-19 
pandemic as well, albeit tainted by the real risks to HCWs 
when performing cardiac imaging. The overarching principle 
when performing cardiac imaging in COVID-19 patients is to 
perform imaging only when the information will impact on the 
TABLE III: Indications and contra-indications for cardiovascular magnetic resonance.
Common indications Contraindications
Accurate assessment of LV function Absolute
Cardiac function and anatomy for device implantation Non-MR compatible implantable devices
Myocardial viability Severe claustrophobia
Detection of intraventricular thrombus
Myocarditis Relative
Myocardial infl ammation/oedema Dysrhythmia affecting ECG gating




Post OHT cardiac surveillance
Constrictive pericarditis
Quantifi cation of valvular function
Aortic and vascular assessments
Iron overload quantifi cation

















FIGURE 1: Approach to cardiac imaging in COVID-19 context.
Meets indication for cardiac imaging?





























Select which cardiac imaging modality is most likely to answer the clinical question*
Withhold imaging, review indication as heart team and image 
at a later stage if unlikely to alter management
Proceed with cardiac imaging with 
appropriate precautions
Suspected COVID-19 Confirmed COVID-19 COVID negative
NOYES
*Avoid using multiple imaging modalities and use the imaging modality that is readily available and has the most expertise.
**TEE should be deferred as far as possible and if absolutely necessary should be done with guideline recommended PPE.
***High risk for coronary artery disease.
312
COVID-19 AND CARDIOVASCULAR IMAGING
immediate management of the patient and to obtain only the 
information required to make the decision.
Echocardiography remains the mainstay of cardiac imaging in 
these patients and CCT and CMR are limited to several specific 
indications. CT in COVID-19 patients is often done for 
pneumonia. When performed, it also creates an opportunity 
to obtain cardiac information (e.g. the presence or absence 
of thrombi in the LAA or LV). Dedicated CCT imaging should 
be reserved for cardiac emergencies such as aortic dissection or 
pulmonary embolism. CMR is a remarkably powerful imaging 
tool, but is generally not recommended in COVID-19 patients 
who are shedding the virus. Its unique ability to provide tissue 
characterisation is arguably a property sought after in the 
management of patients with suspected COVID-19 myocarditis, 
but as it will not affect immediate management, it is not included 
in most current management protocols. Mobility, versatility and 
utility of TTE has earned the echocardiographer the dubious 
honour of being the preferred source of imaging information in 
COVID-19 patients. Given the risk of aerosolisation accom-
panying TEE, it is to be avoided in COVID-19 patients as far 
as possible.
Where possible, the imaging service should aim to retain a 
“clean service” dedicated to non-COVID-19 patients, with a 
limited imaging service dedicated to COVID-19 patients – the 
latter preferably being provided in the COVID-19 areas of 
hospitals, so avoiding transport of patients. At all times, strict 
protocols emphasising physical distancing, mask wearing by 
patients, appropriate PPE utilisation by medical staff, and meti-
culous cleaning practises for staff, equipment and service areas, 
must be practised.
This article provides the reader with compact information and 
a sound approach to delivering a safe cardiovascular imaging 
service during the pandemic. 
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